Pablo Cagnoni

Pablo J.
Cagnoni was the founder of Tizona Therapeutics, Inc., founded in 2015, where the titles held included President, Chief Executive Officer & Director from 2015 to 2018.
Current jobs include Director at Synthekine, Inc. since 2021; Director at Repertoire Immune Medicines, Inc.; Independent Director at Turmeric Acquisition Corp.; President, Head-Research & Development at Incyte Corp.
starting in 2026; Member-Governing Board at Biotechnology Innovation Organization; Member at Council on Foreign Relations, Inc.; and Trustee at Bay Area Discovery Museum.
Former jobs include Chief Executive Officer & Director at Laronde, Inc. from 2022 to 2023; Executive Chairman at Blade Therapeutics, Inc.; Chairman at Rubius Therapeutics, Inc. from 2022 to 2023; Director at Lycera Corp.; Managing Director at MPM BioImpact LLC from 2015 to 2016; Independent Non-Executive Director at CRISPR Therapeutics AG from 2016 to 2020; Director at Harpoon Therapeutics, Inc.; Director at Tango Therapeutics Sub, Inc.; Independent Director at Fusion Pharmaceuticals, Inc. from 2019 to 2024; Chief Medical Officer & Vice President at OSI Pharmaceuticals, Inc. from 2004 to 2007; President at Onyx Pharmaceuticals, Inc. from 2013 to 2015; Chief Medical Officer & Senior Vice President at Allos Therapeutics, Inc. from 2007 to 2009; Senior VP & Global Head-Clinical Development at Novartis AG from 2009 to 2013; Assistant Professor-Medicine at The University of Colorado; and Senior VP & Global Head-Clinical Development at Novartis Oncology, Inc. from 2009 to 2013.
Education includes a doctorate from the University of Buenos Aires School of Medicine.